Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

June 23rd, 2020

New balloon catheter available in US for use in the treatment of patients with peripheral arterial stenoses

Bloomington, Ind. – Cook Medical today announced that the Advance Serenity™ Hydrophilic PTA Balloon Catheter is now available to physicians in the United States. The catheter is manufactured by Surmodics and distributed by Cook Medical.

Advance Serenity is a hydrophilic-coated angioplasty balloon catheter designed to meet the technical needs of clinicians for treatment of patients who suffer from peripheral artery disease (PAD) which includes below-the- knee disease. The catheter portfolio includes both a 0.014- and an 0.018-inch diameter wire guide platform and will be available in a wide variety of balloon lengths and diameters.

“Now that we’ve added Advance Serenity to our product portfolio of vascular solutions, physicians have one more tool in their toolbox to help treat patients who have PAD,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

Cook Medical is working to make Advance Serenity balloon catheters available to physicians in Europe in the coming months. For more details about Advance Serenity, visit the 0.014-inch diameter catheter product page here and the 0.018-inch diameter catheter product page here.

About Cook Medical
Since 1963, Cook Medical has been inventing, manufacturing and delivering a unique portfolio of medical devices to healthcare systems around the world. We work closely with physicians to develop technologies that improve patients’ lives. Because we remain family owned, we have the freedom to focus on what we care about: our patients, our employees and our communities. Find out more at, and for the latest news, follow us on TwitterFacebook and LinkedIn.